Drugs / gp120 (A,B,C,A/E) protein vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03409276 | Mar 2018 → May 2020 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp120 (A,B,C,A/E) protein vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03409276 ↗ |
| Modality | Vaccine | “The protein vaccine included four DNA vaccine-matched GLA-SE-adjuvanted recombinant gp120 proteins.” PMID 38692824 ↗ May 2024 |
| Route | Intramuscular | “Administered by intramuscular injection in the deltoid.” NCT03409276 ↗ |